Chiltern Develops Functional Service Model Relationships in Western Europe
London, UK-September 3, 2009
Chiltern International Limited, a global clinical research organization (CRO) has been selected as the sole provider of clinical research staff for the monitoring aspect of all clinical research projects for Western Europe for a top pharmaceutical company.
All CRAs will be seconded via Chiltern’s European Resourcing Solutions team and fully allocated to the company under a Functional Service or FSP model. The Chiltern CRAs will work directly with the client Project Managers.
Another leading pharmaceutical company also selected Chiltern as the sole provider of an FSP relationship within their pharmacovigilance team. FSP relationships are gaining popularity in the industry due to the flexibility in resource allocations and the cost savings they can offer to clients.
“These are great achievements for Chiltern,” commented Linda Christmas, Chiltern Executive Vice President, Resourcing Solutions, “and helps us meet our target to develop strategically aligned relationships with our clients. We are delighted that we have been able to partner with two more leading pharmaceutical companies in two different core functions.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
